Michigan Congressman Diagnosed With Large B-Cell Lymphoma

Congressman and House Ways and Means Chairman Dave Camp (R-Mich.) was undergoing a routine yearly physical recently when it was determined that he had what the Midwestern legislator described as "a highly treatable and curable type of non-Hodgkins lymphomalarge B-cell lymphoma."

In the approach to this year's election Camp will undergo chemotherapy treatments every three weeks for the next several months. He says he has no intention of letting his diagnosis or his treatment slow him down or prevent him from doing his job on Capitol Hill.

Fortunately, Camp's non-Hogdkins lymphoma was found "very early", meaning it must have been found no later than stage II, possibly even stage I.

Camp to continue working

Rep. Camp plans to forge ahead in public service, saying that,

"In between treatments I will continue my work as a United States Representative for Michigan’s fourth district and as chairman of the Ways and Means Committee."

Furthermore, he reports that his doctors tell him that they expect him to make "a full recovery" and even be cured of the disease.

House Speaker John Boehner (R-Ohio) described Camp as “tough and determined,” in response to news of his colleague’s medical condition.

"He is the epitome of a true gentleman and legislator," said the Speaker, "working tirelessly on behalf of the people and the issues he cares about."

Source: The Hill

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap